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A B S T R A C T
Background
Neurocysticercosis is the most common parasitic infection of the brain. Epilepsy is the most common clinical presentation, though it
may also present with headache, symptoms of raised intracranial pressure, hydrocephalus and ocular symptoms depending upon the
localisation of the parasitic cysts. Anthelmintic drugs, anti-oedema drugs, such as steroids, and antiepileptic drugs (AEDs) form the
mainstay of treatment.
This is an updated version of the original Cochrane Review published in 2015, Issue 10.
Objectives
To assess the eIects (benefits and harms) of AEDs for the primary and secondary prevention of seizures in people with neurocysticercosis.
For the question of primary prevention, we examined whether AEDs reduce the likelihood of seizures in patients who have
neurocysticercosis but have not had a seizure.
For the question of secondary prevention, we examined whether AEDs reduce the likelihood of further seizures in patients who have had
at least one seizure due to neurocysticercosis.
As part of primary prevention studies, we also aimed to examine which AED has been found to be beneficial in people with
neurocysticercosis in terms of duration, dose and side-eIect profile.
Search methods
For the latest update of this review, we searched the following databases on 8 July 2019: Cochrane Register of Studies (CRS Web), MEDLINE
(Ovid, 1946 to July 05, 2019) and LILACS (1982- ). CRS Web includes the Cochrane Epilepsy Group Specialized Register, the Cochrane Central
Register of Controlled Trials (CENTRAL), and randomised or quasi-randomised, controlled trials from Embase, ClinicalTrials.gov and the
World Health Organization International Clinical Trials Registry Platform (ICTRP). We also checked the references lists of identified studies,
and contacted experts in the field and colleagues to search for additional studies and for information about ongoing studies.
Selection criteria
Randomised and quasi-randomised controlled trials.
Single-blind, double-blind or unblinded studies were eligible for inclusion.
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Data collection and analysis
Two review authors screened all citations for eligibility (MS screened the initially identified 180 citations, MF and BDM screened the 48
citations identified for the purpose of this update).Two review authors independently extracted data and evaluated each study for risk of
bias.
Main results
We did not find any trials that investigated the role of AEDs in preventing seizures among people with neurocysticercosis, presenting with
symptoms other than seizures.
We did not find any trials that evaluated evaluating individual AEDs in people with neurocysticercosis.
We found one trial, comparing two AEDs in people with solitary neurocysticercosis with seizures. However, we excluded this study from
the review as it was of poor quality.
We found four trials that compared the eIicacy of short term versus longer term AED treatment for people with solitary neurocysticercosis
(identified on computed tomography (CT) scan) presenting with seizures. In total, 466 people were enrolled. These studies compared
various AED treatment durations, six, 12 and 24 months. The risk of seizure recurrence with six months treatment compared with 12 to
24 months treatment was not statistically significant (odds ratio (OR) 1.34 (95% confidence interval (CI) 0.73 to 2.47; three studies, 360
participants; low-certainty evidence)). The risk of seizure recurrence with six to 12 months compared with 24 months treatment was not
statistically significant (OR 1.36 (95% CI 0.72 to 2.57; three studies, 385 participants; low-certainty evidence)).
Two studies co-related seizure recurrence with CT findings and suggested that persistent and calcified lesions had a higher recurrence risk
and suggest longer duration of treatment with AEDs. One study reported no side eIects, while the rest did not comment on side eIects of
drugs. None of the studies addressed the quality of life of the participants.These studies had certain methodological deficiencies such as
a small sample size and a possibility of bias due to lack of blinding, which aIect the results of this review.
Authors' conclusions
Despite neurocysticercosis being the most common cause of epilepsy worldwide, there is currently no evidence available regarding the
use of AEDs as seizure prophylaxis among people presenting with symptoms other than seizures. For those presenting with seizures, there
is no reliable evidence regarding the duration of treatment required. There is therefore a need for large scale randomised controlled trials
to address these questions.
P L A I N   L A N G U A G E   S U M M A R Y
Treatment of epilepsy in people with neurocysticercosis
Background
Neurocysticercosis is a common infection of the brain caused by the larvae of the pork tapeworm, migrating to the brain. Seizures are the
most common symptom, although some people may present with headache, vomiting or other symptoms of brain swelling.
This review investigates the usefulness of antiepileptic drugs (AEDs) in preventing seizures in people who did not have seizures but
presented with these other symptoms. We also examined the usefulness of the AEDs in people with epilepsy due to neurocysticercosis in
terms of choice of drug, dosage, duration of treatment, cost, side eIects and the quality of life.
Study characteristics
Four trials with a total of 466 participants were reviewed, focusing on the comparison of 'short duration' and 'long duration' of AEDs drugs
in people with a single cerebral lesion. These trials compared various durations of AED therapy: six to 12 months as short duration and 12
to 24 months as long-duration therapy.
Key results
No statistically significant benefit of one duration of AED over the other (six, 12 or 24 months) could be demonstrated. In people with
calcified cysts, longer duration of therapy may be preferable.
All four included trials, enrolled people with a single brain lesion. The findings of our review cannot be extrapolated to people with multiple
cysts or with cysts in unusual parts of the brain.
The evidence is current to July 2019.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Short-duration AED treatment (six months) compared with long-duration AED treatment (12 to 24
months) for people with neurocysticercosis
Short duration AEDs (six months) compared with long duration AEDs (12 to 24 months) for seizure control in people with neurocysticercosis
Patient or population: people with neurocysticercosis
Settings: outpatients, in India
Intervention: short duration AEDs (6 months)
Comparison: long duration AEDS (12 to 24 months)
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Long duration AEDs (12 to
24 months)















121 per 1000 162 per 1000
(88 to 299 per 1000)
OR 1.34






OR > 1 indicates seizure re-
currence is more likely on
short duration AEDs (6
months)
Assumed Risk: The event rate in the long duration AEDs group multiplied by 1000. The event rate is the proportion of the total, in which the event occurred.
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1 Down-graded twice due to lack of blinding of participants and researchers in all the included studies, unclear risk of bias in patient concealment, and lack of applicability.
 
 
Summary of findings 2.   Six to 12 months AED treatment compared with 24 months AED treatment for seizure control in neurocysticercosis
Six to 12 months AED treatment compared with 24 months AED treatment for seizure control in people with neurocysticercosis








































































































































Settings: outpatients, in India
Intervention: 6 to 12 months AED treatment
Comparison: 24 months AED treatment
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
24 months AED treat-
ment














103 per 1000 140 per 1000
(74 to 264 per 1000)






OR > 1 indicates seizure recur-
rence is more likely on 6 to 12
months AED treatment
Assumed Risk: The event rate in the long duration AEDs group multiplied by 1000. The event rate is the proportion of the total, in which the event occurred.
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1 Down-graded twice due to lack of blinding of participants and researchers in all the included studies, unclear risk of bias in patient concealment, and lack of applicability.
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B A C K G R O U N D
This review is an update of a previously published review in
The Cochrane Database of Systematic Reviews (2015, Issue 10;
Sharma 2015) on Antiepileptic drugs for seizure control in people
with neurocysticercosis.
Description of the condition
Neurocysticercosis is an infection of the central nervous system
by Taenia solium cysticerci. Taenia solium is an intestinal parasite
that infests animals such as pigs and has a secondary life cycle in
human beings. Ingestion of the parasite eggs, excreted in the faeces
of the pig or an infested human host, can result in cysticercosis.
AOer ingestion, the eggs can migrate from the gut to lodge in various
tissues of the body, where they form cysts. Cysticercosis is usually
asymptomatic. When symptoms of cysticercosis do develop it is
usually due to cysticercal invasion of the central nervous system
and eyes.
Neurocysticercosis is the most common parasitic infection of the
brain. The prevalence of neurocysticercosis is high in low- and
middle-income countries where there is close proximity between
humans and pigs. It is common in much of South and Central
America, China, the Indian subcontinent, South-East Asia, and
sub-Saharan Africa. It aIects around 50 million people worldwide
(Dhawan 2011), with men and women equally aIected, and has
a peak incidence at ages 30 to 40 years (Zafar 2013). However,
migration of populations has changed the epidemiology of the
disease and the prevalence of the disease in developed countries is
now increasing.
The presentation of neurocysticercosis is related to the site of
invasion by the cyst, the stage of the parasite and the host immune
response. Cysts in the cerebral parenchyma are noted to have
four stages - vesicular stage, colloidal stage, granulomatous stage
and calcified stage (DeGiorgio 2004; García 2002). The vesicular
stage is the viable cyst which is associated with a minimal
immune response and hence shows limited enhancement aOer
intravenous contrast in neuroimaging. Although an eccentric scolex
may be seen with magnetic resonance imaging (MRI) within the
cyst at this stage. The second stage is where the viable cyst
ruptures to release its fluid in the surrounding parenchyma.
This fluid stimulates an intense immune response in the host
and results in perilesional oedema which is associated with
contrast enhancement on MRI. This is the most common clinically
evident stage of neurocysticercosis. Cellular response to this stage
results in the next granulomatous (or nodular) stage during which
some perilesional oedema may still be visible. The final stage
of destruction and calcification may result in permanent calcific
lesions in the parenchyma. There may also be a conglomeration
of cysts in the basal cisterns (termed racemose cysts). Single cysts
are usually up to 20 mm in diameter. Giant cysts more than 50 mm
in diameter may produce space-occupying eIects. Cysts may also
occur within the ventricles or in the spinal cord.
Epilepsy is an important neurological condition characterised
by recurrent seizures, and has an estimated annual incidence
of 50/100,000 and a prevalence of five to 10/1000 in the
developed world (Sander 1996). Approximately three per cent of
the population will suIer from seizures at some point in their lives
(Hauser 1992). Epilepsy can have several causes, for example, head
injury, infections of the brain, tumours, infarcts and haemorrhage.
Neurocysticercosis is an important cause of symptomatic seizures
or secondary epilepsy among children and adults in many low- and
middle-income countries. In some countries neurocysticercosis
has been reported to be the cause of 20% to 70% of cases of
symptomatic epilepsy (Daniels 2006; Del Brutto 2005; Palacio 1998;
Rajshekhar 2006). In some Asian countries, neurocysticercosis
causes up to 50% cases of epilepsy Rajshekhar 2003), and up to 90%
of cases of symptomatic seizures in children (Singhi 2000).
Seizures are the most common first presenting feature of
neurocysticercosis, occurring in nearly 70% to 90% of patients
(DeGiorgio 2004). The seizures are usually partial seizures, with
or without secondary generalisation (Del Brutto 1992; Singhi
2000). Host immune response (resulting in oedema and/or gliosis
surrounding the cysts) and calcification are the reasons for
epileptogenesis (the gradual process during which a previously
normal brain develops epilepsy) in neurocysticercosis (Pradhan
2000). Multiple parenchymal cysts are associated with more
frequent seizures (Ferreira 2002). A smaller but significant number
of patients may present with severe and recurrent headaches.
Localisation in the ventricles or in the basal cisterns may result
in development of hydrocephalus causing severe headache and
features of raised intracranial pressure. In addition, cysticercostic
encephalitis is a rare clinical presentation of neurocysticercosis
(García 2002).
The diagnosis of neurocysticercosis is established on the basis
of clinical presentation and computed tomography (CT) scan or
MRI. Diagnostic criteria proposed by Rajshekhar and Brutto (Del
Brutto 2001; Rajshekhar 2003) includes these features and can be
used to define the disease The clinical and radiological diagnosis
can be supported by serological tests such as enzyme-linked
immunosorbent assay (ELISA) and enzyme-linked immuno transfer
blot test (ELITB), which have been found to be highly specific for the
diagnosis (Dhawan 2011).
Description of the intervention
As seizures are the most common presentation of
neurocysticercosis, antiepileptic drugs (AEDs) are oOen used. The
duration of AED therapy has been based on expert opinions or
consensus. Most experts recommend that AEDs be continued
until the epileptogenic focus, in the form of the oedema or the
degenerating cyst, resolves completely. This may be a variable
period of up to six months. However, as some of the lesions
may resolve as a calcified lesion in the parenchyma, they may
continue to be a focus for seizures. The benefit of longer-term
AED therapy on seizure frequency has not been established (Gupta
2002; Thussu 2002; Verma 2006). Seizure recurrence in people
with neurocysticercosis is usually associated with the presence
of multiple parenchymal cysts, frequent seizures before the start
of treatment with AEDs, and persistent calcification (Del Brutto
1996; Gupta 2002; Rajshekhar 2004; Thussu 2002). Monotherapy
with carbamazepine or phenytoin is the common choice for seizure
control. A small proportion may require polytherapy (Rajshekhar
2004).
How the intervention might work
AEDs are important in the control of seizures, which are the most
common presentation of neurocysticercosis. These drugs help to
prevent the recurrence of seizures in patients with symptomatic
epilepsy secondary to neurocysticercosis and may have a role in
Antiepileptic drugs for seizure control in people with neurocysticercosis (Review)
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primary prevention of seizures in people with neurocysticercosis
who present with features other than seizures, such as headache or
altered behavior.
Why it is important to do this review
The management of an individual with neurocysticercosis imposes
a great burden on the economy of the world, costing an estimated
0.0037% of the gross national product for one treatment of all
the neurocysticercosis patients in one country (Murthy 2007; Pal
2000). Solitary neurocysticercosis is essentially self-limiting and
presents clinically when the viable cysts actually start degenerating
to produce an immune response. The use of anthelmintic treatment
has been a subject of debate and is the topic of another Cochrane
Review (Abba 2010). Short courses of steroids (oral prednisolone)
are used to control the host response and pericystic oedema.
For people with symptomatic epilepsy secondary to
neurocysticercosis, there are no systematic reviews on which
AED to use, what dosage to prescribe, or how long to treat for.
In addition, for those with neurocysticercosis who present with
symptoms other than seizures, there are no systematic reviews on
the use of AEDs to prevent seizures occurring. Hence, we undertook
a systematic review of the role of AEDs in the treatment of people
with neurocysticercosis presenting with or without seizures.
O B J E C T I V E S
To assess the eIects (benefits and harms) of antiepileptic drugs
(AEDs) for the primary and secondary prevention of seizures in
people with neurocysticercosis.
1. For the question of primary prevention, we examined whether
AEDs reduce the likelihood of seizures in patients who have
neurocysticercosis but have not had a seizure.
2. For the question of secondary prevention, we examined whether
AEDs reduce the likelihood of further seizures in patients who
have had at least one seizure due to neurocysticercosis.
3. As part of primary prevention studies, we also aimed to examine
which AED has been found to be beneficial in people with
neurocysticercosis in terms of duration, dose and side-eIect
profile.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled trials.
Single-blind, double-blind or unblinded studies were eligible for
inclusion.
For studying primary prevention, we planned to include
studies where individuals with neurocysticercosis presented with
symptoms other than seizures, such as headache or behavioural
changes.
For secondary prevention, we planned to include studies where
the participants had neurocysticercosis with seizures prior to
randomisation.
Types of participants
We included studies of people with neurocysticercosis, diagnosed
on the basis of neuroimaging findings, with or without additional
serological or histopathological confirmation.
We excluded studies on neurocysticercosis at extracerebral sites.
The participants were of all age groups (children and adults)
and  both genders.  The participants may have had any type of
seizures associated with neurocysticercosis or presented with
symptoms other than seizures.
Types of interventions
The intervention group may have received any of the currently
marketed AEDs, in addition to the usual treatment for
neurocysticercosis (anthelmintics or steroids, or both). The controls
may have received placebo or only the usual treatment for
neurocysticercosis without AEDs. The AEDs may have been a single
drug (monotherapy) or in combination. The duration of treatment
may have been short (a few weeks or months) or prolonged (years).
Types of outcome measures
Primary outcomes
1. Proportion of individuals experiencing seizures.
2. Time to first seizure post randomisation.
Secondary outcomes
1. Proportion of individuals who were seizure free for a specific
time period (12 or 24 months).
2. Proportion of individuals who withdrew from treatment.
3. Proportion of individuals who developed drug-related side
eIects or complications.
4. For studies comparing short versus long duration of treatment,
proportion of individuals who were seizure free with each
treatment policy.
5. Quality of life (measured by validated scales).
6. Cost of therapy.
7. Requirement for hospitalisation, need for intensive care
treatment and length of hospitalisation.
8. Mortality.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published or unpublished, in press, or in
progress).
Electronic searches
Searches for the original review were run in April 2014. Subsequent
searches were run in May 2015, December 2016, and June 2018. For
the latest update, we searched the following databases on 8 July
2019.
1. Cochrane Register of Studies (CRS Web), using the search
strategy outlined in Appendix 1.
2. MEDLINE (Ovid, 1946 to July 05, 2019), using the search strategy
outlined in Appendix 2.
3. LILACS (1982- ), using the search strategy outlined in Appendix 3.
Antiepileptic drugs for seizure control in people with neurocysticercosis (Review)
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CRS Web includes the Cochrane Epilepsy Group Specialized
Register, the Cochrane Central Register of Controlled Trials
(CENTRAL), and randomised or quasi-randomised, controlled trials
from Embase, ClinicalTrials.gov and the World Health Organization
International Clinical Trials Registry Platform (ICTRP).
Searching other resources
We also checked the references list in the selected studies and tried
to contact researchers in the field to look at unpublished data. We
contacted experts in the field and colleagues and asked if they were
aware of any studies which we may have missed in our searches. We
also tried to identify any ongoing studies from registries of clinical
trials.
Data collection and analysis
We analysed the data using Cochrane's Review Manager
soOware,RevMan 5.3 (RevMan 2014). The primary analysis was
intention-to-treat analysis. We calculated odds ratio (OR) for
dichotomous data (proportion of individuals experiencing seizures,
seizure free for a specific time period (12 or 24 months),
withdrew from treatment, developed drug-related side eIects
or complications, were seizure-free with each treatment policy,
mortality), and planned to use mean diIerence (MD) for continuous
data, if any continuous data were identified (quality of life, cost
of treatment). We intended to evaluate time to first seizure aOer
randomisation by hazard ratios (HRs). We assessed precision using
95% confidence intervals (CIs).
We stratified the analysis by treatment comparison. We also
considered the duration of the drugs used, co-medications used
and the length of follow-up.
Selection of studies
The review authors (MS, MF and BDM) independently screened all
citations and abstracts and evaluated the eligibility of each study
for the review. MS screened the initially identified 180 citations,
MF and BDM screened the 48 citations identified for the purpose
of this update. We included studies on the basis of the criteria
earlier described in Criteria for considering studies for this review.
We excluded studies that were not eligible and documented the
reasons for exclusion.
Data extraction and management
Two review authors (MS, AM) independently extracted data using
a tailored data extraction form. We summarised and coded data
on study design, participant characteristics, interventions, and
outcomes and entered them into RevMan (RevMan 2014). We
resolved any discrepancies between data extracted by the two
authors by discussion and by referring to the third review author.
We extracted the following data.
1. Trial factors:




e. duration of study;
f. duration of follow-up.
2. Participants:
a. number in each group;
b. age and sex distribution per randomised group;
c. seizure type and frequency per randomised group;
d. number of seizures before randomisation in each group;
e. other neurologic deficits;
f. neuroimaging data: location of lesion; number of lesions-
solitary or multiple, nature of cyst - live or dying or calcified.
3. Type of intervention:
a. AED studied;
b. number of drugs used;
c. duration of AED;
d. adjunctive medications used in each group.
4. Outcome measures (as described earlier).
5. Withdrawals from study.
Assessment of risk of bias in included studies
Two review authors (MS, AM) assessed each trial independently. We
resolved any disagreements by consensus, or with consultation of
a third party (TS) in case of disagreement. We assessed risk of bias
using Cochrane's 'Risk of bias' tool (Higgins 2011).
We used the following criteria.
1. Was the allocation sequence adequately generated?
2. Was the allocation adequately concealed?
3. Was knowledge of the allocated intervention adequately
prevented during the study?
4. Were incomplete outcome data adequately addressed?
5. Are reports of the study free of suggestion of selective outcome
reporting?
6. Was the study apparently free of other problems that could put
it at a high risk of bias?
We used individual bias items as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011). A
'Risk of bias' graph figure and 'Risk of bias' summary figure can be
accessed here (Figure 1; Figure 2).
We planned to explore the influence of individual 'Risk of bias'
criteria in a sensitivity analysis.
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Figure 1.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 2.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
 
Measures of treatment e>ect
We measured treatment eIect as the proportion of individuals in
each group who were seizure free for a specific time period (six,12 or
24 months). We calculated ORs for dichotomous data and planned
to use MD for continuous data. We assessed precision using 95%
CIs.
We planned to measure the adverse eIect of treatment as the
proportion of individuals withdrawn from the study due to adverse
eIects of the drugs. We also planned to try to measure and compare
the adverse eIects between short and long duration of treatment
in studies that compared short and long duration of treatment.
We carried out an analysis of three studies comparing six months
AED with 12 to 24 months AED and of three studies comparing six
to 12 months versus 24 months AED therapy.
Unit of analysis issues
We intended to take into account the level at which randomisation
occurred, such as cross-over trials, cluster-randomised trials and
multiple observations for the same outcome. However, none of the
studies included in the review are cross-over or cluster-randomised
trials.
Dealing with missing data
We procured the complete article for collection of data. In case of
missing data (number of patients excluded, reasons), we contacted
the principal investigator of the study by email. Up until the time of
writing the review, we had not received any replies.
Antiepileptic drugs for seizure control in people with neurocysticercosis (Review)
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Assessment of heterogeneity
We assessed heterogeneity between trials by examining the forest
plot, and using the I2 statistic for heterogeneity, where an I2 greater
than 50% indicates substantial heterogeneity
We assessed clinical heterogeneity by comparing the diIerences
in demographics, type and number of seizures, type of AED used,
dosages and duration of treatment and radiological data in the
various studies.
Assessment of reporting biases
We assessed the included studies for reporting bias by evaluating
the exclusion criteria in the study and also by evaluating the
dropout rate and noting the reasons for it. We also assessed the
probability of publication bias by examining a funnel plot for
asymmetry.
Data synthesis
We combined dichotomous data by the method of Mantel Haenzsel
using a fixed-eIect model.
Subgroup analysis and investigation of heterogeneity
We had planned to undertake subgroup analysis for the following
subgroups:
1. individuals with a single granuloma and those with multiple
cerebral granulomas;
2. individuals with neurocysticercosis treated with monotherapy
and polytherapy;
We did not find any studies comparing treatment in people with
single and multiple granulomas or that compared monotherapy
versus polytherapy.
Sensitivity analysis
We carried out a sensitivity analysis to test the robustness of meta-
analysis.
Summarising and interpreting results
Two 'Summary of findings' tables have been created; one table
for each comparison (six months AED treatment versus 12 to
24 months AED treatment and six to 12 months AED treatment
versus 24 months AED treatment), including the primary outcome
of proportion of individuals experiencing seizure recurrence
(Summary of findings for the main comparison, Summary of
findings 2). The other primary outcome of the review, time to
first seizure aOer randomisation was not reported in any of the
included studies. If this outcome is reported in included studies
in future updates of the review, it will be added to the 'Summary
of findings' tables. The certainty of the evidence was determined
using the GRADE approach (GRADEPro 2004); where evidence
was downgraded in the presence of high risk of bias in at least
one trial, indirectness of the evidence, unexplained heterogeneity
or inconsistency, imprecision of results, high probability of
publication bias. Evidence was downgraded by one level if the
limitation was considered serious and two levels if considered very
serious; as judged by the review authors.
R E S U L T S
Description of studies
The review authors (MS, MF, BDM) independently reviewed the
results of the electronic search to identify relevant trials for the
complete review.
Results of the search
A total of 228 records were identified through database searching,
including 48 newly identified trials and a further three records
were identified through other sources. We removed duplicate
citations and obviously irrelevant items (i.e. not reports of trials),
trials studying the use of albendazole, praziquantel and their
combinations and trials studying various protocols of steroids
for people with neurocysticercosis. Of the 85 remaining records,
78 were excluded as they were studies addressing laboratory
diagnosis of neurocysticercosis or trials for which the outcomes
reported were an assessment of the impact of non-AED medicines
such as anthelmintics and/or steroids.
We found seven potentially relevant studies for the review. Full
published texts of the articles of these seven publications were
reviewed. Three were excluded and we finally included four studies.
The review authors decided which studies should be included for
the review aOer discussion. The inclusion, exclusion criteria and
methodological quality were graded on a pre designed format.
The review authors were not blinded to the study authors names,
institute of the studies and the journal of publication. The search
results are shown in Figure 3.
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Figure 3.   Study flow diagram.
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Figure 3.   (Continued)
 
Included studies
We identified four studies, which together enrolled 466 patients
with neurocysticercosis. One study (Singhi 2003) included children
between the ages of three and 14 years; one study (Verma 2006)
included adults (age not specified); one study (Thussu 2002)
included both children and adults, ages varying from four to 52
years; and one study (Gupta 2002) did not clearly mention the age
range of patients included in the study. Three studies (Singhi 2003;
Thussu 2002; Verma 2006) enrolled patients from outpatient clinics
whereas Gupta 2002 did not mention the source of patients.
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Of the 466 people involved, the gender of 81 people included
in one study (Gupta 2002) was not specified. Of the rest, 237
were male and 148 were female participants. Partial seizures were
the commonest form of seizures. Forty-two people had primary
generalised seizures and 343 people had partial seizures. One
study (Gupta 2002) did not elaborate on the type of seizures and
drugs given. In the other three studies, 299 people were given
carbamazepine and 105 people received phenytoin.
All the studies included were single-centre studies carried out at
various centres in India. A total of 466 people were included in
the trials. These studies compared eIicacy of various durations
(six, 12 and 24 months) of AED therapy. Three studies (Gupta 2002;
Thussu 2002; Verma 2006) considered six months AED treatment as
short duration and one study (Singhi 2003) considered 12 months
treatment as short duration. Twelve months was considered as long
duration of treatment in Gupta 2002 and three studies (Singhi 2003;
Thussu 2002 Verma 2006) considered 24 months as long duration
of treatment. One hundred and eight-six people in three studies
(Gupta 2002; Thussu 2002; Verma 2006) received six months of AED
and 55 people in one study (Singhi 2003) received 12 months AED as
short duration. One hundred and eighty-five people in three studies
(Singhi 2003; Thussu 2002 Verma 2006) received 24 months AED as
long duration and 40 people in one study (Gupta 2002) received 12
months AED as long duration of treatment.
Patients were followed up for a period of 12 months in three
studies (Gupta 2002; Singhi 2003; Thussu 2002) and for 18 months
in one (Verma 2006) aOer randomisation. Repeat neuroimaging was
performed in three studies; at three or six months in two studies
(Gupta 2002; Verma 2006) and at 12 months in one study (Singhi
2003) aOer an initial scan at randomisation.
The common AEDs used were carbamazepine or phenytoin. Two
studies (Singhi 2003; Verma 2006) stated that choice of drug was
decided by the treating physician and possibly aIected by cost of
treatment. One study (Thussu 2002) did not state the reason, if
any, for choice of a particular AED. The fourth study (Gupta 2002)
focused on the comparison of the duration of AED given and did not
state which drug was given. This adds an element of bias in choice
of therapy and aIects outcome and we judged it as high risk of other
bias.
Details of each of the included studies are further described in
Characteristics of included studies.
Excluded studies
We excluded three studies. One study (Chang 1998) was a small
case series of add-on treatment with tiagabine in adults with
neurocysticercosis receiving AEDs for seizure control. The second
study (Kaushal 2006) compared the tolerability and eIicacy and
safety of clobazam with phenytoin sodium. We excluded this
study as the participants in this open-label pilot study were only
observed for six months and the authors do not provide 12 months
follow-up data on the outcome measures required in this review.
The third study (Lanchote 2002) investigated the pharmacokinetic
interactions between AEDs and serum albendazole enantiomer
concentrations.
Risk of bias in included studies
The risk of bias is demonstrated in Figure 1 and Figure 2 and
detailed below.
Allocation
The method used for randomisation was stated in three studies
(Singhi 2003; Thussu 2002; Verma 2006), whereas Gupta 2002
did not state the method of randomisation. Methods used for
randomisation included a lottery system (Thussu 2002), coin
toss (Verma 2006) and random number tables (Singhi 2003). We
assumed that randomisation was done appropriately and thus
there was a low risk of allocation bias.
There is an unclear risk of allocation concealment bias in all four
studies (Gupta 2002; Singhi 2003; Thussu 2002; Verma 2006) as
concealment has not been mentioned.
Blinding
None of the studies mention blinding of participants or treating
physicians to the study arm or to the antiepileptic agent being
used. In two studies (Singhi 2003; Verma 2006) the choice of drug
used depended upon the physician and aIordability of the agent.
We report a high risk of performance bias and an unclear risk of
detection bias in all four studies (Gupta 2002; Singhi 2003; Thussu
2002; Verma 2006).
Incomplete outcome data
One study (Verma 2006) detailed the number of patients excluded
from the study due to loss to follow-up and fulfilment of exclusion
criteria. We judged a low attrition bias in this study. The other
three studies (Gupta 2002; Singhi 2003; Thussu 2002), mentioned
exclusion criteria but did not detail the number of patients excluded
in the final analysis. We judged a unclear attrition bias in these
studies.
Selective reporting
The protocols of the selected studies were not available for
comparison with the final conduct of the studies. We judged two
studies (Singhi 2003, Verma 2006) to have a low risk of reporting
bias as evident from the reported results in the studies. We judged
two studies (Gupta 2002, Thussu 2002) to have an unclear risk of
reporting bias.
E>ects of interventions
See: Summary of findings for the main comparison Short-
duration AED treatment (six months) compared with long-
duration AED treatment (12 to 24 months) for people with
neurocysticercosis; Summary of findings 2 Six to 12 months AED
treatment compared with 24 months AED treatment for seizure
control in neurocysticercosis
All four studies included in the review compared the eIectiveness
of short-term versus long-term antiepileptic drugs (AED) treatment
in seizure control in people with neurocysticercosis. All included
studies recruited patients with seizures prior to AED treatment
therefore analyses are of secondary prevention as opposed to
primary prevention.
Primary Outcomes
None of the identified studies randomised individuals to
specific AEDs and none compared the proportion of individuals
experiencing seizures between the AEDs prescribed.
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Secondary Outcomes
Three studies (Gupta 2002; Thussu 2002; Verma 2006) considered
six months as short-term treatment, whereas Singhi 2003
considered patients treated for 12 months as the short-term group.
Gupta 2002 considered 12 months as the long-duration treatment
arm and the other three studies (Singhi 2003; Thussu 2002; Verma
2006) considered 24 months treatment as the long-duration arm.
Three studies (Gupta 2002; Singhi 2003; Thussu 2002) followed up
patients for 12 months aOer stopping AED while one study (Verma
2006), followed up patients for 18 months. The outcome seizure
recurrence was recorded from patient reports on follow-up visits
every two or three months aOer randomisation.
We analysed data comparing six months AED treatment versus 12
to 24 months AED treatment (data from three studies (Gupta 2002;
Thussu 2002; Verma 2006)) and data comparing six to 12 months
AED treatment versus 24 months AED treatment (data from three
studies (Singhi 2003; Thussu 2002; Verma 2006)).
The odds ratio (OR) of seizure recurrence with six months AED
treatment compared with 12 to 24 months AED treatment was
not statistically significant (OR 1.34, 95% CI 0.73 to 2.47; three
studies; 360 participants; low-certainty evidence; (Figure 4, Analysis
1.1)). The risk of seizure recurrence with six to 12 months AED
treatment compared with 24 months AED treatment was also not
statistically significant (OR 1.36, 95% CI 0.72 to 2.57; three studies,
385 participants; low-certainty evidence; (Figure 5; Analysis 2.1)).
 




Figure 5.   Forest plot of comparison: 2. 6-12 months AED treatment versus 24 months AED treatment, outcome: 2.1
Seizure recurrence.
 
Two studies (Singhi 2003; Verma 2006) correlated seizure
recurrence with CT findings. Both studies suggest that prolonged
AED treatment may be required for patients with persistent lesions
or calcification, based on seizure recurrence and follow-up CT
scanning.
Only one study (Verma 2006) mentioned that no side eIects
occurred in any patient. The other three studies (Gupta 2002; Singhi
2003; Thussu 2002) did not comment on side eIects of AEDs in their
patients.
The cost of treatment, quality of life, mortality, and requirement for
hospitalisations were not evaluated in any of the studies.
The dosage of drug used was mentioned in one study (Verma 2006);
no information was provided on drug doses in the other three
studies. Therefore, we did not carry out subgrouping of drug given
or dosage for this review.
D I S C U S S I O N
We intended to look at trials evaluating the eIicacy of various
antiepileptic drugs (AEDs) for seizure control in people with
neurocysticercosis. For primary prevention, we intended to look at
patients with neurocysticercosis presenting with problems other
than seizures for example, headache, diplopia (double vision) etc.
However, in our electronic search we did not find trials addressing
the above. This finding indicates a gap in our knowledge base and
the need for randomised controlled trials to address this issue.
For secondary prevention, we aimed to look at studies that
considered whether AEDs decrease the likelihood of further
seizures in patients who have experienced at least one seizure.
Summary of main results
We found seven trials of apparent relevance. One study (Chang
1998) was excluded as it was a description of four cases.
One study (Kaushal 2006) compared the safety and eIicacy of
clobazam versus phenytoin sodium in seizure control in people
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with a single neurocysticercosis. This study was excluded as it
was of poor quality. The third excluded study (Lanchote 2002)
investigated the pharmacokinetic interactions between AEDs and
serum albendazole enantiomer concentrations.
The four studies included in the review compared the use of short
duration and long duration AED treatment in control of seizures in
people with a single cerebral cysticercal cyst.
Four hundred and sixty-six people with neurocysticercosis
participated in the four included studies (Gupta 2002; Singhi
2003; Thussu 2002; Verma 2006). These studies examined seizure
recurrence with varying durations of AED treatment (six or 12 or 24
months).
The odds ratio (OR) of seizure recurrence with six months AED
treatment compared with 12 to 24 months treatment was not
statistically significant (OR 1.34; 95% CI 0.73 to 2.47; three studies,
360 participants (186 participants for six months treatment and
174 participants for 12 to 24 months treatment) (Analysis 1.1)). The
risk of seizure recurrence with six to 12 months AED treatment
compared with 24 months treatment was also not statistically
significant (OR 1.36; 95% CI 0.72 to 2.57; three studies, 385
participants (200 participants randomised to six to 12 months
treatment and 185 participants to 24 months treatment) (Analysis
2.1)).
Two studies (Singhi 2003; Verma 2006) indicated that in cases where
a persistence of lesion or calcification is found on review computed
tomography (CT) scans, prolongation of AED treatment may be
eIective in optimal seizure control.
Overall completeness and applicability of evidence
A major drawback of the four studies included in the review,
comparing short-duration and long-duration treatments, is that
none of the studies sought to establish the eIectiveness of the
specific AED being given, with respect to choice of drug, dosage,
compliance or side-eIect profiles. All four studies solely focused on
comparison of duration of drugs being given. The results thus have
limited applicability to choice of AED for physicians.
With the exception of Verma 2006, where exclusions and losses are
detailed, none of the included studies mentioned the exact number
of people excluded from the trial and why.
Most studies mentioned that neurocysticercosis is a benign and
oOen a self-limiting condition. Thus patient selection may aIect
the final outcome of the studies. Two studies (Thussu 2002; Verma
2006) excluded patients who had a persistence of lesion, which is
actually a high risk for seizure recurrence, implying that patients
selected for the study had a low risk of seizure recurrence in the first
place.
Most of the studies included in the review excluded patients with
persistent lesions and those needing albendazole therapy, some
of whom may have actually been potential candidates for seizure
recurrence. As a result, the study inferences prevent generalisation
to all patients will neurocysticercosis and rather focuses on patients
with inactive parasitic cysts.
Also, all of the included studies focused on people with a
solitary cerebral lesion. These factors limit the applicability and
generalisation of the study results as evidence for future use in
people with neurocysticercosis who may have multiple cysts or the
lesion is situated in unusual locations for example, intra ventricular
cysts, brainstem cysts etc .
Three of the studies (Gupta 2002; Singhi 2003; Verma 2006)
correlated seizure recurrence and the need for prolonged therapy
with the presence of a calcified lesion. They suggest that people
with calcified lesions would benefit with a longer duration of AEDs
and additionally helped by repeated neuroimaging to check the
status of the lesion. This suggestion is useful in practice.
Certainty of the evidence
The studies that compared short-duration and long-duration AEDs
included in this review have methodological deficiencies, such
as lack of blinding, small sample sizes, reporting biases, lack of
description of withdrawals from the study. We graded the level of
evidence as low. All the included studies had an inherent bias in
patient allocation and blinding. Though not clearly mentioned, it
can be assumed that the treating physicians and patients were not
blinded to the study drug and study arm being studied. This also
adds a possibility of a reporting bias, all of which together aIect the
quality of evidence provided by the study results.
We evaluated the included studies for heterogeneity using the I2
statistic (I2 = 0%). The studies included in the meta-analysis, were
homogenous with respect to diagnostic criteria used, method of
sampling, method of observation, follow-up and analysis of results.
The forest plot of comparison shows a trend (not statistically
significant) in favour of a longer duration of AED treatment over a
short duration of treatment for seizure recurrence (OR 1.34; 95% CI
0.73 to 2.47) for six months versus 12 to 24 months AED treatment
(Analysis 1.1) and (OR 1.36; 95% CI 0.72 to 2.57) for six to 12 months
versus 24 months AED treatment (Analysis 2.1).
An analysis of the findings is shown in the Summary of findings for
the main comparison and Summary of findings 2. We graded the
level of evidence as low.
Potential biases in the review process
Potentially, studies may have been missed by the search strategy if
smaller studies were presented at clinical conferences, but not in
the literature identified through the search engines employed.
None of the identified studies reported the primary outcome
measures of the proportion of individuals experiencing seizures
or the time to first seizure between AED treatment groups. We
contacted the authors to attempt to obtain these data but did
not receive these data to undertake these analyses. Nevertheless,
had these data been made available, there would potentially be
significant bias as the prescription of AEDS was not randomised
but rather determined by the clinician, which reflects clinical and
potentially financial bias.
Study selection potentially could have introduced bias as in the
protocol we limited our inclusion to studies with at least 12 months
of data, therefore we are unable to comment on the eIicacy of AEDs
in the first six months of therapy.
All four included studies were single-centre studies from various
parts of India. The geographic location and disease behaviour
outcomes may be diIerent in the subcontinent versus other regions
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of the world where neurocysticercosis is equally rampant. We
cannot rule out a regional bias in this review.
We generated a funnel plot indicating a publication bias in the
included studies Figure 6. The quality of the trials included is not
uniform, in terms of study design. For example, one study enrolled
children only (Singhi 2003), one study included only adults (Verma
2006), while one included people of all age ranges (Thussu 2002).
The mean age of people in the latter study (Thussu 2002) was in the
adult range. The fourth study (Gupta 2002),did not specify details of
the enrolled patients, such as age, gender or type of seizures. This
factor aIects the result of this review.
 
Figure 6.   Funnel plot of comparison: 2. 6-12 months AED treatment versus 24 months AED treatment, outcome: 2.1
Seizure recurrence.
 
Agreements and disagreements with other studies or
reviews
So far, there have been reviews on treatment of people
with neurocysticercosis, highlighting anthelmintic therapy, anti-
oedema measures such as steroids and various combinations of
these measures with respect to seizure control (Abba 2010; García
2002; Zafar 2013). While most of these reviews mention the need
for AEDs in patients presenting with seizures, there are no reviews
dedicated to the use of AEDs with respect to drug choices, duration
of treatment, side-eIect profiles etc.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The initial research question for this review was: ‘Do
antiepileptic drugs (AEDs) influence seizure control in people
with neurocysticercosis with respect to the drug used, dose and
duration?' We also intended to look at primary prevention in
people with symptoms other than seizures. We do not know
whether prophylactic AED therapy is useful in preventing seizures
in people with neurocysticercosis presenting with symptoms other
than seizures, since no randomised controlled trials are available at
present.
We found only one study that compared two AEDs in people with
solitary cerebral cysticercosis. We excluded this study as it was of
poor quality and had a limited follow-up period of only six months.
We cannot suggest superiority of one AED over another.
We found four studies that addressed duration of AED for seizure
control in people with a single cerebral cyst. Our analysis does
not suggest a clear benefit of short (six to 12 months) or longer
duration of AED (12 to 24 months). In people with persistent cysts
or calcification, we found low-certainty evidence that a longer
duration of AED treatment may reduce seizures compared to a
shorter duration of AED treatment.
Implications for research
Further studies are needed to determine which AED is more suitable
for persons with seizures (or epilepsy) due to neurocysticercosis
and what is the optimal dose range and duration of treatment.
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Studies are also needed to address the issue whether prophylactic
treatment with AEDs reduce the occurrence of seizures. The
eIect of AED treatment on quality of life for people with
neurocysticercosis also needs to be investigated.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomised trial.
Method of randomisation not stated.
Single centre in New Delhi, India.
Total duration of trial 1.5 to 2 years in both study groups.
Ethical approval/consents not stated.
Participants 81 participants, 41 people with NCC treated for 6 months in group A, 40 people with NCC treated for a
period of 12 months in group B.
Gupta 2002 
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Diagnostic criteria based on CT Scan findings.
Age and sex distribution not stated.
Inclusion criteria: all patients with epilepsy and diagnostic CT findings, only patients with a single le-
sion.
Exclusion criteria: suspected tuberculoma and NCC patients treated with albendazole.
Follow-up: 12 months after drug withdrawal.
Interventions AED treatment for seizure control for 6 months in group A and 12 months in group B.
Details of drug used, dosage in either groups not stated.
Outcomes Seizure recurrence after stoppage of treatment.
Notes Single outcome studied. Withdrawls and exact number of excluded patients not stated. Choice of AED
not mentioned. Dosage, side effects, cost and impact on quality of life not studied.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not detailed
Allocation concealment
(selection bias)





High risk Not mentioned in article, probably not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Withdrawals, exclusions and reasons (if any) not stated
Selective reporting (re-
porting bias)
Unclear risk Protocol not available. Insufficient information to comment on reporting




Methods Randomised controlled trial.
Single centre in India.
Total duration of trial 2-3 years in both comparison groups.
Participants Children with NCC.
Singhi 2003 
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Diagnostic criteria based on CT Scan findings, only single lesions included.
55 children treated with AEDs for 1 year as group A, 51 children treated for 2 years as group B.
Age range: 3 to 14 years, 61 boys, 45 girls.
Demographically comparable groups.
Inclusion criteria: children with seizures and CT scan diagnosis of NCC.
Exclusion criteria: children with multiple or calcified CT lesions, static or progressive neurological dis-
order, any systemic or chronic illness, any clinical or ancillary evidence of tuberculosis;
55% also received albendazole within 3 months of presentation.
Follow-up: 12 months after drug withdrawal.
Interventions AEDs for 12 months in group A and 24 months in group B.
All children received monotherapy.
80% received carbamazepine, 18% received dilantin.
Formulations, dosage, group-wise distribution not stated.
Outcomes Seizure recurrence during and after drug withdrawal.
Association of seizure recurrence with clinical variables (type and frequency of seizures).
Association of seizure recurrence with CT and EEG abnormalities.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequence tables used for randomisation
Demographic variables of children in both groups comparable









High risk Participants and personnel were not blinded to the intervention. Hence, we as-
sume here that they were also not blinded to short or long duration treatment
arms.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Withdrawals and reasons not stated
Selective reporting (re-
porting bias)
Low risk Study protocol not available, all expected outcomes suitably detailed in the re-
sults section
Singhi 2003  (Continued)
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Methods Randomised clinical trial.
Single centre in India.
Duration of trial 1.5-3 years in two groups.
Participants People with seizures and CT scan suggestive of NCC
Age range: 4 to 52 years, Mean ages in group A and B 19.5 ± -8.79 years and 25.6 ± 12.5 years, respective-
ly. 53% of patients were males.
Total: 73 people, 47 in group A treated with AEDs for 6 months, 26 in group B treated for 24 months.
Follow-up: every 2 months for 12 months after withdrawal of drugs.
Exclusion criteria: people with persistent lesions requiring albendazole therapy.
Interventions AEDs for 6 months in group A, 24 months in group B.
Group A 25 received carbamazepine, 22 received phenytoin.
Group B 13 each received carbamazepine and phenytoin.
Exact dosage and formulations not stated. Mentioned to have received quote: "therapeutic dosage ac-
cording to weight".
Outcomes Seizure recurrence after withdrawal of AED.
Correlation of seizure recurrence with CT Scan findings.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation based on lottery system
Allocation concealment
(selection bias)





High risk Not stated
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Number of patients excluded or withdrawing from the study not mentioned
Thussu 2002 
Antiepileptic drugs for seizure control in people with neurocysticercosis (Review)









Cochrane Database of Systematic Reviews
Selective reporting (re-
porting bias)
Unclear risk Protocol not available. Insufficient information to confirm reporting bias.





Methods Randomised clinical trial.
Single centre in India.
Duration of trial 2 to 3.5 years in two groups.
Participants 227 people with NCC, 206 randomised.
Inclusion criteria: people with epilepsy with CT Scan criteria of Del Brutto et al. Only people with com-
plete resolution of lesion at 3 to 6 months CT scan or presence of calcified residua included.
Exclusion criteria: persistent lesions on repeat CT scan at 3 to 6.months interval.
Mean age 21.8 ± 6.1 years in group A, 19.5 ± 8.8 years in group B.
Gender distribution in two groups comparable.
Seizure type, duration at randomisation and frequency comparable in the two groups.
Follow-up for a minimum of 18 months after drug withdrawal.
Interventions AEDs for 6 months in Group A and 24 months in Group B.
176 people treated with carbamazepine (600 to 1000 mg/day).
51 people treated with phenytoin (300 to 400 mg/day).
Outcomes Seizure recurrence during and after withdrawal of AED.
Severe side effects to AED.
Correlation of seizure recurrence with CT scan finding in follow-up scans.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Simple random sampling by coin toss method
Allocation concealment
(selection bias)
Unclear risk Authors do not detail the conduct of the coin toss and wether result of the coin





High risk Not stated
Verma 2006 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Number of people lost to follow-up in both groups and number of people com-
pleting study mentioned in table 1
Selective reporting (re-
porting bias)
Low risk Study protocol not available, no differences between planned and reported
outcomes evident







Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Chang 1998 Case series study of 4 adult patients with NCC with epilepsy. Tiagabine HCL was used as an add-on
drug in 4 patients (2 on carbamazepine and 2 on phenytoin).
Kaushal 2006 Comparison of clobazam with phenytoin sodium for prevention of seizures in people with single
NCC. This is an underpowered study which was prematurely terminated due to relocation of one
of the authors. The reason for the difference in numbers between the two comparison groups is
not clear. It is not clear whether the two groups were balanced as far as the prognostic variables
are concerned. The number of participants randomised to phenytoin and clobazam differ in the
text and in the CONSORT flow chart. The study planned to enrol 135 participants in each of the two
groups, in order to provide sufficient power to detect 10% difference in the primary outcome mea-
sure with 90% confidence. The numbers accrued, however fell short on account of premature ter-
mination of the study.
Lanchote 2002 The objective of this study was to determine the interaction between the AEDs and the selective
metabolism of albendazole. In this study plasma concentrations of albendazole sulfoxide (ASOX)
and albendazole sulphone (ASON) metabolites were measured in 32 adults who received pheny-
toin, carbamazepine, phenobarbital or no AED. None of the primary or secondary outcome mea-






D A T A   A N D   A N A L Y S E S
 
Comparison 1.   6 months AED treatment versus 12 to 24 months AED treatment




Statistical method Effect size
1 Seizure recurrence 3 360 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.73, 2.47]
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Analysis 1.1.   Comparison 1 6 months AED treatment versus 12
to 24 months AED treatment, Outcome 1 Seizure recurrence.
Study or subgroup 6 months AED 12-24
months AED
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Gupta 2002 5/41 5/40 24.69% 0.97[0.26,3.65]
Thussu 2002 8/47 3/26 17.81% 1.57[0.38,6.53]
Verma 2006 16/98 13/108 57.5% 1.43[0.65,3.14]
   
Total (95% CI) 186 174 100% 1.34[0.73,2.47]
Total events: 29 (6 months AED), 21 (12-24 months AED)  
Heterogeneity: Tau2=0; Chi2=0.3, df=2(P=0.86); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
Favours 6 months AED 1000.01 100.1 1 Favours 12-24 months AED
 
 
Comparison 2.   6 to 12 months AED treatment versus 24 months AED treatment




Statistical method Effect size
1 Seizure recurrence 3 385 Odds Ratio (M-H, Fixed, 95% CI) 1.36 [0.72, 2.57]
 
 
Analysis 2.1.   Comparison 2 6 to 12 months AED treatment
versus 24 months AED treatment, Outcome 1 Seizure recurrence.
Study or subgroup 6-12
months AED
24 months AED Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Singhi 2003 3/55 3/51 17.84% 0.92[0.18,4.8]
Thussu 2002 8/47 3/26 19.43% 1.57[0.38,6.53]
Verma 2006 16/98 13/108 62.73% 1.43[0.65,3.14]
   
Total (95% CI) 200 185 100% 1.36[0.72,2.57]
Total events: 27 (6-12 months AED), 19 (24 months AED)  
Heterogeneity: Tau2=0; Chi2=0.27, df=2(P=0.88); I2=0%  
Test for overall effect: Z=0.96(P=0.34)  
Favours 6-12 months AED 1000.01 100.1 1 Favours 24 months AED
 
 
A P P E N D I C E S
Appendix 1. CRS Web search strategy
1. MeSH DESCRIPTOR Neurocysticercosis Explode All AND CENTRAL:TARGET
2. neurocysticercosis AND CENTRAL:TARGET
3. MeSH DESCRIPTOR Taenia solium Explode All AND CENTRAL:TARGET
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4. "Taenia solium" AND CENTRAL:TARGET
5. tapeworm OR "tape worm" AND CENTRAL:TARGET
6. #1 OR #2 OR #3 OR #4 OR #5 AND CENTRAL:TARGET
7. MeSH DESCRIPTOR Epilepsy Explode All WITH QUALIFIER DT AND CENTRAL:TARGET
8. MESH DESCRIPTOR Seizures EXPLODE ALL WITH QUALIFIER DT AND CENTRAL:TARGET
9. MeSH DESCRIPTOR Anticonvulsants Explode All AND CENTRAL:TARGET
10. MeSH DESCRIPTOR Midazolam Explode All AND CENTRAL:TARGET
11. MeSH DESCRIPTOR Methazolamide Explode All AND CENTRAL:TARGET
12. MeSH DESCRIPTOR Propofol Explode All AND CENTRAL:TARGET
13. MeSH DESCRIPTOR Temazepam Explode All AND CENTRAL:TARGET
14. MeSH DESCRIPTOR Thiopental Explode All AND CENTRAL:TARGET
15. (antiepilep* or anti-epilep* or anticonvulsant* or anti-convulsant* or AED or AEDs):AB,KW,MC,MH,TI AND CENTRAL:TARGET
16. (Acetazolamid* or Aedon or Aethosuximide or Alodorm or Amizepin* or Antelepsin or Anxirloc or Arem or Ativan or Atretol or
Avugane):AB,KW,MC,MH,TI AND CENTRAL:TARGET
17. (Baceca or Barbexaclon* or Beclamid* or Biston or Bomathal or Brivaracetam or Bromid*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
18. (Calepsin or Carbagen or Carbamazepen* or Carbamazepin* or Carbatrol or Carbazepin* or Carbelan or Carisbamat* or Castilium or
CBZ or Celontin or Cerebyx or Chlonazepam or Chloracon or Chlorepin or Clorepin or Chlormethiazole or Clormethiazole or Clarmyl or
Cloazepam or Clobam* or Clobator or Clobazam or Clofritis or Clonazepam* or Clonex or Clonopin or Clopax or Clorazepate or Comfyde
or Convulex):AB,KW,MC,MH,TI AND CENTRAL:TARGET
19. (Dapaz or Dasuen or Delepsine or Depacon or Depak* or Depamide or Deproic or Desitin or Diacomit or Diamox or Diastat or
Diazepam or Difenilhidantoin* or Dihydantoin or Dilantin or Dimethadione or Dimethyloxazolidinedione or Diphenin* or Diphenylan or
Diphenylhydantoin* or Distraneurin or Divalpr* or Dormicum):AB,KW,MC,MH,TI AND CENTRAL:TARGET
20. (Ecovia or Emeside or Epanutin or Epiject or Epilepax or Epilex or Epilim or Episenta or Epitol or Epival or Eptoin or Equanil or Equetro or
Ergenyl or Erimin or Erlosamide or Eslicarbazepine or Estazolam or Ethadione or Ethosucci* or Ethosuxi* or Ethotoin or Ethylphenacemide
or Etosuxi* or Euhypnos or Exalief or Excegran or Ezogabine):AB,KW,MC,MH,TI AND CENTRAL:TARGET
21. (Fanatrex or Felbam* or Felbatol or Fenitoin* or Fenytoin* or Fenobarbit* or Finlepsin or Fosphenytoin or Frisium or
Fycompa):AB,KW,MC,MH,TI AND CENTRAL:TARGET
22. (Gabapentin* or Gabapetin* or Gabarone or Gabitril or Gabrene or Ganaxolone or Garene or Gralise or Grifoclobam):AB,KW,MC,MH,TI
AND CENTRAL:TARGET
23. (Halogabide or Halogenide or Harkoseride or Hibicon or Hydroxydiazepam or Hypnovel):AB,KW,MC,MH,TI AND CENTRAL:TARGET
24. (Iktorivil or Inovelon or Insoma or Intensl or Karbamazepin or Karidium or Keppra or Klonopin or Kriadex):AB,KW,MC,MH,TI AND
CENTRAL:TARGET
25. (Lacosamid* or Lamict* or Lamitor or Lamitrin or Lamogine or Lamotrigin* or Lamotrine or Landsen or Levanxol or Levetiracetam* or
Lexin or Liskantin or Loraz or Lorazepam* or Losigamon* or Lucium or Luminal or Lyrica):AB,KW,MC,MH,TI AND CENTRAL:TARGET
26. (Magnesium sulfat* or Magnesium sulphat* or Mebaral or Medazepam or Mephenytoin or Mephobarbit* or Mephyltaletten or
Meprobamate or Meprospan or Mesantoin or Mesuximide or Methazolamid* or Methsuximide or Methylacetazolamide or Methyloxazepam
or Methylphenobarbit* or Midazolam or Miltown or Mogadon or Mylepsinum or Mylproin or Mysoline or Mystan):AB,KW,MC,MH,TI AND
CENTRAL:TARGET
27. (Neogab or Neptazane or Nesdonal or Neurontin or Neurotop or Nimetazepam or Nitrados or Nitrazadon or Nitrazepam or
Nobrium or Nocturne or Noiafren or Norkotral or Normison or Normitab or Nortem or Novo-Clopate or Nuctalon or Nupentin or
Nydrane):AB,KW,MC,MH,TI AND CENTRAL:TARGET
28. (OCBZ or Onfi or Orfiril or Orlept or Ormodon or Ospolot or Oxcarbamazepin* or Oxcarbazepin* or Oxydiazepam):AB,KW,MC,MH,TI AND
CENTRAL:TARGET
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29. (Pacisyn or Paraldehyde or Paramethadione or Paxadorm or Paxam or Peganone or Penthiobarbital or Pentothal or Perampanel
or Petinutin or Petril or Phemiton or Phenacemide or Pheneturide or Phenobarbit* or Phensuximide or Phenylethylbarbit* or
Phenylethylmalonylurea or Phenytek or Phenytoin* or Planum or Posedrine or Potiga or Pregabalin or Primidone or Prodilantin or
Progabide or Prominal or Pronervon or Propofol or Prosom or Prysoline):AB,KW,MC,MH,TI AND CENTRAL:TARGET
30. (Ravotril or Remacemide or Remestan or Remnos or Resimatil or Restoril or Retigabine or Riluzole or Rilutek or Rivotril or Rudotel or
Rufinamide or Rusedal or "RWJ-333369"):AB,KW,MC,MH,TI AND CENTRAL:TARGET
31. (Sabril or Seclar or Sederlona or Selenica or Seletracetam or Sentil or Sertan or Sibelium or Signopam or Sirtal or Sodipental or Somnite
or Stavzor or Stazepin* or Stedesa or Stiripentol or Sulthiam* or Sultiam*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
32. (Talampanel or Taloxa or Tasedan or Tegretal or Tegretol or Telesmin or Temaze or Temazep* or Temesta or Temtabs or Tenox or Teril
or Thiomebumal or Thionembutal or Thiopent* or Tiagabin* or Tiletamine or Timonil or Tiobarbit* or Tipiram* or Topamax or Topiram* or
Tranmep or Tranxene or Trapanal or Tridione or Trileptal or Trimethadione or Trobalt):AB,KW,MC,MH,TI AND CENTRAL:TARGET
33. (Urbadan or Urbanil or Urbanyl):AB,KW,MC,MH,TI AND CENTRAL:TARGET
34. (Valance or Valcote or Valium or Valnoctamide or Valparin or Valpro* or Versed or Vigabatrin* or Vimpat or Visano or
VPA):AB,KW,MC,MH,TI AND CENTRAL:TARGET
35. (Xilep or "YKP 509" or Zalkote or Zarontin or Zebinix or Zonegran or Zonisamid*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
36. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR
#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 AND CENTRAL:TARGET
37. #6 AND #36
Appendix 2. MEDLINE search strategy




4. exp Taenia solium/
5. (tape worm or tapeworm).tw.
6. 1 or 2 or 3 or 4 or 5
7. exp *Epilepsy/dt [Drug Therapy]







15. (antiepilep$ or anti-epilep$ or anticonvulsant$ or anti-convulsant$ or AED or AEDs).tw.
16. (Acetazolamid$ or Aedon or Aethosuximide or Alodorm or Amizepin$ or Ant?lepsin or Anxirloc or Arem or Ativan or Atretol or
Avugane).tw.
17. (Baceca or Barbexaclon$ or Beclamid$ or Biston or Bomathal or Brivaracetam or Bromid$).tw.
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18. (Calepsin or Carbagen or Carbamazepen$ or Carbamazepin$ or Carbatrol or Carbazepin$ or Carbelan or Carisbamat$ or Castilium or
CBZ or Celontin or Cerebyx or Chlonazepam or Chloracon or C?lorepin or C?lormethiazole or Clarmyl or Cloazepam or Clobam$ or Clobator
or Clobazam or Clofritis or Clonazepam$ or Clonex or Clonopin or Clopax or Clorazepate or Comfyde or Convulex).tw.
19. (Dapaz or Dasuen or Delepsine or Depacon or Depak$ or Depamide or Deproic or Desitin or Diacomit or Diamox or Diastat or
Diazepam or Difenilhidantoin$ or Dihydantoin or Dilantin or Dimethadione or Dimethyloxazolidinedione or Diphenin$ or Diphenylan or
Diphenylhydantoin$ or Distraneurin or Divalpr$ or Dormicum).tw.
20. (Ecovia or Emeside or Epanutin or Epiject or Epilepax or Epilex or Epilim or Episenta or Epitol or Epival or Eptoin or Equanil or Equetro or
Ergenyl or Erimin or Erlosamide or Eslicarbazepine or Estazolam or Ethadione or Ethosucci$ or Ethosuxi$ or Ethotoin or Ethylphenacemide
or Etosuxi$ or Euhypnos or Exalief or Excegran or Ezogabine).tw.
21. (Fanatrex or Felbam$ or Felbatol or Fenitoin$ or Fenobarbit$ or Fenytoin$ or Finlepsin or Fosphenytoin or Frisium or Fycompa).tw.
22. (Gabapentin$ or Gabapetin$ or Gabarone or Gabitril or Gabrene or Ganaxolone or Garene or Gralise or Grifoclobam).tw.
23. (Halogabide or Halogenide or Harkoseride or Hibicon or Hydroxydiazepam or Hypnovel).tw.
24. (Iktorivil or Inovelon or Insoma or Intensl or Karbamazepin or Karidium or Keppra or Klonopin or Kriadex).tw.
25. (Lacosamid$ or Lamict$ or Lamitor or Lamitrin or Lamogine or Lamotrigin$ or Lamotrine or Landsen or Levanxol or Levetiracetam$ or
Lexin or Liskantin or Loraz or Lorazepam$ or Losigamon$ or Lucium or Luminal or Lyrica).tw.
26. (Magnesium sulfat$ or Magnesium sulphat$ or Mebaral or Medazepam or Mephenytoin or Mephobarbit$ or Mephyltaletten or
Meprobamate or Meprospan or Mesantoin or Mesuximide or Methazolamid$ or Methsuximide or Methylacetazolamide or Methyloxazepam
or Methylphenobarbit$ or Midazolam or Miltown or Mogadon or Mylepsinum or Mylproin or Mysoline or Mystan).tw.
27. (Neogab or Neptazane or Nesdonal or Neurontin or Neurotop or Nimetazepam or Nitrados or Nitrazadon or Nitrazepam or Nobrium or
Nocturne or Noiafren or Norkotral or Normison or Normitab or Nortem or Novo-Clopate or Nuctalon or Nupentin or Nydrane).tw.
28. (OCBZ or Onfi or Orfiril or Orlept or Ormodon or Ospolot or Oxcarbamazepin$ or Oxcarbazepin$ or Oxydiazepam).tw.
29. (Pacisyn or Paraldehyde or Paramethadione or Paxadorm or Paxam or Peganone or Penthiobarbital or Pentothal or Perampanel
or Petinutin or Petril or Phemiton or Phenacemide or Pheneturide or Phenobarbit$ or Phensuximide or Phenylethylbarbit$ or
Phenylethylmalonylurea or Phenytek or Phenytoin$ or Planum or Posedrine or Potiga or Pregabalin or Primidone or Prodilantin or
Progabide or Prominal or Pronervon or Propofol or Prosom or Prysoline).tw.
30. (Ravotril or Remacemide or Remestan or Remnos or Resimatil or Restoril or Retigabine or Riluzole or Rilutek or Riv?tril or Rudotel or
Rufinamide or Rusedal or "RWJ-333369").tw.
31. (Sabril or Seclar or Sederlona or Selenica or Seletracetam or Sentil or Sertan or Sibelium or Signopam or Sirtal or Sodipental or Somnite
or Stavzor or Stazepin$ or Stedesa or Stiripentol or Sulthiam$ or Sultiam$).tw.
32. (Talampanel or Taloxa or Tasedan or Tegret?l or Telesmin or Temaze or Temazep$ or Temesta or Temtabs or Tenox or Teril or
Thiomebumal or Thionembutal or Thiopent$ or Tiagabin$ or Tiletamine or Timonil or Tiobarbit$ or Tipiram$ or Topamax or Topiram$ or
Tranmep or Tranxene or Trapanal or Tridione or Trileptal or Trimethadione or Trobalt).tw.
33. (Urbadan or Urban?l).tw.
34. (Valance or Valcote or Valium or Valnoctamide or Valparin or Valpro$ or Versed or Vigabatrin$ or Vimpat or Visano or VPA).tw.
35. (Xilep or "YKP 509" or Zalkote or Zarontin or Zebinix or Zonegran or Zonisamid$).tw.
36. or/7-35
37. 6 and 36
38. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
39. clinical trials as topic.sh.
40. trial.ti.
41. 38 or 39 or 40
42. exp animals/ not humans.sh.
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43. 41 not 42
44. 37 and 43
45. remove duplicates from 44
Appendix 3. LILACS search strategy
(anticonvulsant OR mh:("anticonvulsants")) AND (mh:("NEUROCYSTICERCOSIS" OR "TAENIA") OR neurocysticercosis OR taenia OR (tape
AND worm) OR tapeworm)
W H A T ' S   N E W
 
Date Event Description
8 July 2019 New search has been performed Searches updated 8 July 2019; no new trials identified.




C O N T R I B U T I O N S   O F   A U T H O R S
MS independently screened all 180 citations and abstracts and evaluated the eligibility of the study for the review. MF and BDM
independently screened 48 newly identified citations and abstracts and evaluated the eligibility of the study for the review. MS and AM
independently extracted data using a tailored data extraction form. TS supervised data extraction and resolved any discrepancies between
MS and AM, if needed. MS prepared the first draO of the review. TS reviewed the final draO.





BDM has received funding from the NIHR, Wellcome Trust, Academy of Medical Sciences, British Medical Association.
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute of Health Research, UK.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the protocol, we planned to analyse seizure control with AEDs over a specified period of time. We had also planned to look at studies
comparing duration of treatment with respect to seizure control. A subgroup analysis between patients with single versus multiple cerebral
lesions and monotherapy versus polytherapy was planned.
In the final review, we were restricted to comparing short-duration versus long-duration therapy according to the studies identified
and included in the review. All the included studies were carried out on people with single cerebral lesions and all patients received
monotherapy. The intended subgroup analysis was hence not possible.
In the protocol, we had mentioned that we would exclude studies comparing two AEDs. However, we decided to include such studies aOer
this oversight was pointed out in the review process. This was essential to answer our primary question of "which AED is better for seizure
control?"
In the protocol, we intended to look at the eIect of drugs in seizure control in a population with neurocysticercosis and therefore planned to
calculate the risk ratio (RR). As we were able to find studies that compared short duration versus long duration AED treatment, we calculated
the odds ratio (OR) to look at the odds of seizure recurrence in long duration of AED treatment against short duration of treatment.
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As far as the search methods, data collection and analysis are concerned, we were able to proceed as per the protocol design.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants  [*therapeutic use];  Brain Diseases  [*complications]  [parasitology];  Carbamazepine  [therapeutic use];  Epilepsy
 [drug therapy];  Neurocysticercosis  [*complications];  Phenytoin  [therapeutic use];  Randomized Controlled Trials as Topic;  Seizures
 [etiology]  [*prevention & control]
MeSH check words
Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male; Middle Aged
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